The 20 Best Triple-Negative Breast Cancer Doctors in The United States

Dr. O'Shaughnessy is a Medical Oncologist that focuses on breast cancer prevention and treatment. She founded The School of Breast Oncology, a program providing a curriculum-based program focused exclusively on breast cancer clinical management. Dr. O'Shaughnessy attended medical school at Yale University School of Medicine in New Haven, CT. She then completed her Internal Medicine residency at Massachusetts General Hospital in Boston, MA and a Medical Oncology fellowship at National Cancer Institute in Bethesda, MD. She is co-chair of Breast Cancer Research, chair of Breast Cancer Prevention Research at Baylor Charles A. Sammons Cancer Center and a member of the Scientific Advisory Board for US Oncology Research Network. Dr. O'shaughnessy is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 14 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Inflammatory Breast Cancer, and Tissue Biopsy. Dr. O'shaughnessy is board certified in Medical Oncology- American Board Of Internal Med/Medical Oncology, Internal Medicine- American Board Of Internal Med, Internal Medicine- American Board Of Internal Medicine, and Medical Oncology- American Board Of Internal Medicine.

Dr. Alastair Thompson is a surgical oncologist specializing in breast cancer. He is the Professor and Chief of the Division of Surgical Oncology, Section of Breast Surgery at Baylor College of Medicine, where he holds the Olga Keith Wiess Chair of Surgery. He also serves as Co-Director of the Lester and Sue Smith Breast Center and is Co-Associate Director for Clinical Research at the Dan L Duncan Comprehensive Cancer Center.Dr. Thomspon’s clinical interests include: ductal carcinoma in situ (DCIS); nipple and skin sparing mastectomy; breast conservation surgery; and sentinel lymph node biopsy. His research interests include: multidisciplinary patient care alongside “bench to bedside” studies; and innovative clinical trials in cancer. He initiated and led a successful breast cancer laboratory program; provided leadership for a cancer center in the United Kingdom; chaired the UK national breast cancer trials portfolio of 120 studies; and engaged in a range of pivotal roles in key drug, radiation therapy and surgical trials involving the UK, Europe, United States and Australia.Dr. Thompson also has preclinical and practical experience in the design, implementation, monitoring and reporting of early- to late-phase drug and medical device trials. Dr. Thompson received his MBChB in Medicine Surgery and medical degree in Molecular Biology from the University of Edinburgh in Edinburgh, Scotland. He completed his residency in general surgery at the Royal Infirmary of Edinburgh and a Research Fellowship at the Imperial Cancer Research Fund in Edinburgh.Dr. Thompson has co-chaired the Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for low-risk DCIS; and the National Cancer Institute (NCI)-Breast Cancer Steering Committee proposed “no surgery” clinical trial planning committee. He is a member of the NCI BOLD taskforce and has held leadership positions in the Translational Breast Cancer Research Consortium and SWOG Cancer Research Network.Dr. Thompson is also a member of the American Society of Clinical Oncology, Association of Breast Surgery, British Association of Surgical Oncology, British Breast Group, American Society of Breast Surgeons, American Association for Cancer Research, Moynihan Chirurgical Club, and the Society of Surgical Oncology. Dr. Thompson is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. He is also highly rated in 6 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Mastectomy, and Tissue Biopsy. Dr. Thompson is currently accepting new patients.

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 16 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer. Dr. Tolaney is board certified in Medical Oncology.

My clinical practice if focused on the care of patients with breast cancer, particularly those diagnosed at a younger age and those with recurrence in the central nervous system. I am committed to the care of patients with breast cancer brain metastases, and I am honored to serve as the Medical Director of the Brain and Spine Metastases Program in the Duke Cancer Center. In this role, our multidisciplinary team provides well-coordinated care for patients with breast cancer and other solid tumor types that have metastasized to the central nervous system. In addition, I enjoy helping young women diagnosed with breast cancer navigate their treatment decisions to ensure both excellent medical care and attention to individual challenges, such as future fertility, sequelae of treatment on longer-term health, and impact on current and future relationships. When not working, I enjoy running, reading, and traveling with my family. Dr. Anders is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Brain Tumor, Triple-Negative Breast Cancer, and Metastatic Brain Tumor.

Dr. Lin is a medical oncologist specializing in the care of patients with all stages of breast cancer. Her research focuses upon improving the outcomes of people living with metastatic breast cancer, including a particular focus on the challenge of breast cancer brain metastases. She has led multiple clinical trials which have led to new treatment options for patients with breast cancer that has metastasized to the brain. Dr. Lin received her MD from Harvard Medical School in 1999. She completed her residency in internal medicine at Brigham and Women's Hospital and went on to complete fellowships in medical oncology and hematology at Dana-Farber. In 2005, she joined the staff of Brigham and Women's and Dana-Farber, where she is a medical oncologist and clinical investigator in the Breast Oncology Center. Dr. Lin is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 13 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Brain Tumor, and Inflammatory Breast Cancer. Dr. Lin is board certified in Medical Oncology.

Adam M. Brufsky, MD, PhD, FACP, is professor of medicine at the University of Pittsburgh School of Medicine and also serves as the associate division chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine's Department of Medicine. Dr. Brufsky is the medical director of the Magee-Women's Cancer Program, part of the UPMC Hillman Cancer Center, and UPMC Hillman Cancer Center; associate director for clinical investigations at UPMC Hillman Cancer Center; and codirector of the Comprehensive Breast Cancer Center.Dr. Brufsky is board-certified in internal medicine and medical oncology. He earned a medical and doctor of philosophy degrees from the University of Connecticut School of Medicine in Farmington, Conn.; completed a residency at Brigham and Women's Hospital, Harvard Medical School, and a fellowship at Dana-Farber Cancer Institute.Dr. Brufsky is a member of professional organizations, such as American Medical Association, Massachusetts Medical Society, American College of Physicians, American Society of Clinical Oncology, American Association for Cancer Research, Allegheny County Medical Society, Pennsylvania Medical Society, and Pennsylvania Oncologic Society. An active researcher, Dr. Brufsky has numerous abstracts and research articles in leading journals, and is principal investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army - Breast Cancer Research Program. Dr. Brufsky is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Gastrostomy. Dr. Brufsky is board certified in American Board Of Internal Medicine and American Board Of Internal Medicine. Dr. Brufsky is currently accepting new patients.

Dr. Antonio Wolff is internationally recognized for his work on breast cancer biomarkers, including HER2. As a practicing oncologist and clinical translational researcher, his research has been pivotal to improve the quality of breast cancer biomarker testing in breast cancer, including HER2 and estrogen receptor testing. Among his leadership accomplishments is ensuring that sophisticated laboratory findings are translated into improved clinical care in breast cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO), a Komen Scholar and a Breast Cancer Research Foundation investigator. He has served as associate editor for Journal of Clinical Oncology, and serves on the National Comprehensive Cancer Network (NCCN) Guideline Steering Committee. He is a leader of the Translational Breast Cancer Research Consortium (TBCRC), and one of the principal investigators of the Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies (EVOLVE) in Metastatic Breast Cancer, which was one of the three disease groups recently awarded by ARPA-H to conduct innovative trials using Advanced Analysis for Precision Cancer Therapy (ADAPT). After many years of service as Breast Committee Chair in the ECOG-ACRIN Clinical Trial Network of the National Cancer Institute (NCI), he was elected in 2024 as Co-Chair of the NCI Breast Cancer Steering Committee and appointed to the international steering committee of the Oxford Overview Collaborative, which are positions aimed at advancing clinical trials in breast cancer. At Johns Hopkins, he is an elected member of the Miller Coulson Academy of Clinical Excellence and was honored during the 125th Anniversary Living the Hopkins Mission celebrations of the JHU School of Medicine. Dr. Wolff is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, and Inflammatory Breast Cancer. Dr. Wolff is board certified in American Board Of Internal Medicine.

Bridgette Collins is an Endocrinologist practicing medicine in New Orleans, Louisiana. Dr. Collins is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 5 other conditions, according to our data. Her clinical expertise encompasses Triple-Negative Breast Cancer, Breast Cancer, Paget Disease of the Breast, and Inflammatory Breast Cancer.

Lajos Pusztai is an Oncologist practicing medicine in New Haven, Connecticut. Dr. Pusztai is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Triple-Negative Breast Cancer, Breast Cancer, Inflammatory Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and Tissue Biopsy.

Hope Rugo is an Oncologist practicing medicine in San Francisco, California. Dr. Rugo is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 19 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Bone Marrow Aspiration, and Hormone Replacement Therapy (HRT).

Aditya Bardia is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Bardia is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Triple-Negative Breast Cancer, Agranulocytosis, and Tissue Biopsy.

Joanne Mortimer is an Oncologist practicing medicine in Duarte, California. Dr. Mortimer is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, HER-2 Positive Breast Cancer, and Colonoscopy.

Kathy Miller is an Oncologist practicing medicine in Indianapolis, Indiana. Dr. Miller is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Breast Cancer in Men, and Salpingo-Oophorectomy.

Vered Stearns is an Oncologist practicing medicine in New York, New York. Dr. Stearns is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 8 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, and Paget Disease of the Breast.

Denise Yardley is an Oncologist practicing medicine in Nashville, Tennessee. Dr. Yardley is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, and Paget Disease of the Breast. Dr. Yardley is currently accepting new patients.

James Ingle is an Oncologist practicing medicine in Virginia Beach, Virginia. Dr. Ingle is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Menopause, and HER-2 Positive Breast Cancer.

Foluso Ademuyiwa is an Oncologist practicing medicine in Saint Louis, Missouri. Dr. Ademuyiwa is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, Paget Disease of the Breast, and Angiosarcoma.

Dr. Sofia Merajver received a doctoral degree in physics from the University of Maryland and a medical degree from the University of Michigan. She completed a residency in internal medicine and a fellowship in oncology at the University of Michigan before joining the faculty in 1994. Dr. Merajver, an expert in breast cancer genetics, is the medical director of the Breast and Ovarian Cancer Risk Evaluation Program at the U-M Rogel Cancer Center. Her research interests include the molecular genetics of breast cancer, gene function and cancer risk assessment. She enjoys literature, music and outdoor activities with her family. Dr. Merajver is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, and Angiosarcoma. Dr. Merajver is board certified in Medical Oncology.

Dr. Radha Iyengar is the medical director of the Breast Center at Texas Health Presbyterian Hospital Allen. She obtained her undergraduate and medical degrees from the University of Florida and went on to complete a general surgery residency at the University of Texas Southwestern Medical School in Dallas. She then completed a Society of Surgical Oncology accredited breast fellowship at Emory University in Atlanta before returning to Texas.Dr. Iyengar is board-certified by the American Board of Surgery and is a Fellow of the American College of Surgeons. She is a member of the American College of Surgeons, Dallas Medical Society, American Society of Breast Surgeons, American Society of Breast Disease and American Society of Clinical Oncology. Dr. Iyengar is rated as an Advanced provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, Intraductal Papilloma, and Lymphadenectomy.

Stacy Moulder is a primary care provider, practicing in Internal Medicine in Cary, North Carolina. Dr. Moulder is rated as an Elite provider by MediFind in the treatment of Triple-Negative Breast Cancer. She is also highly rated in 4 other conditions, according to our data. Her clinical expertise encompasses Triple-Negative Breast Cancer, Breast Cancer, PIK3CA-Related Overgrowth Spectrum, and HER-2 Positive Breast Cancer.